Detalhe da pesquisa
1.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist
; 24(6): e327-e337, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796151
2.
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Cancer Immunol Immunother
; 68(1): 97-107, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30311027
3.
Predictors of mood disorders in cancer patients' caregivers.
Support Care Cancer
; 21(2): 643-7, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23203651
4.
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
J Pers Med
; 13(3)2023 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36983597
5.
Treatment-related side effects and quality of life in cancer patients.
Support Care Cancer
; 20(10): 2553-7, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22270087
6.
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
Cancers (Basel)
; 14(15)2022 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35954369
7.
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.] / Gestione del paziente con microcitoma nelle regioni Lazio, Umbria e Sardegna.
Recenti Prog Med
; 112(10): 639-646, 2021 10.
Artigo
em Italiano
| MEDLINE | ID: mdl-34647533
8.
Investigating Serum and Tissue Expression Identified a Cytokine/Chemokine Signature as a Highly Effective Melanoma Marker.
Cancers (Basel)
; 12(12)2020 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33302400
9.
Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Front Immunol
; 11: 579894, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33072126
10.
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
J Exp Clin Cancer Res
; 38(1): 272, 2019 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31227006
11.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
J Immunother Cancer
; 7(1): 57, 2019 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30813970
12.
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
Oncotarget
; 9(27): 18997-19005, 2018 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29721178
13.
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Front Immunol
; 9: 403, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29531523
14.
Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.
Oncotarget
; 8(45): 79809-79815, 2017 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29108362
15.
Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.
Oncotarget
; 8(69): 113472-113493, 2017 Dec 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29371923
16.
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Front Immunol
; 8: 386, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28446908
17.
Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.
Int J Oncol
; 48(4): 1581-9, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26846845
18.
Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Int J Oncol
; 49(3): 1164-74, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27572607
19.
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.
Eur J Cancer
; 97: 59-61, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743138